Halozyme Therapeutics, Inc. (HALO)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $12.76B
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 2, 2026
Profit #210 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 25.3% | 21.8% | 20.2% | 31.0% |
Growth #109 of 1484 companies
Payout #801 of 1484 companies
Safety #1123 of 1484 companies
Price #603 of 1484 companies
